• MindMaze posted a net loss of CHF 6.93 million, compared with CHF 3.29 million a year earlier.
• Revenue rose to CHF 513,000 from CHF 32,000, while operating loss widened to CHF 6.71 million from CHF 5.15 million.
• Cash and cash equivalents fell to CHF 5.32 million from CHF 9.47 million at Dec. 31, 2025.
• Group expects existing liquidity to fund operations into the fourth quarter of 2026, with CHF 4 million committed financing available.
• CEO Zach Henderson highlighted U.S. pipeline growth, Vibra real-world evidence results, and a pharma distribution launch phase expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindMaze Therapeutics Holding SA published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.